Business Intelligence for the Pharmaceutical Industry
The portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our healthcare research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report...
• The HIV market is forecast to expand at a CAGR of 10.3% over the period 2006-12. Growth is forecast to be driven by gains in the launch of new drug classes of drugs such as integrase, entry and maturation inhibitors.
• NRTIs lead the HIV market in 2006 with a market share of 51.5% having captured $4,671m in sales. The key growth driver in this drug class has been the increasing use of fixed-dose NRTI combinations, such as Gilead’s Truvada and GSK’s Combivir.
• The introduction of entry inhibitors in 2003 contributed significantly to the global HIV market, with sales of ‘other’ HIV treatments accruing $405m in 2006, representing a formidable CAGR of 265.7% over the 2002-06 period.
• The NRTI drug class is set to be transformed by patent expiries including BMS’s Videx (didanosine), Roche’s Hivid, and the expected patent expiry of Zerit in July 200 with the influx of generics.
• In 2006, 98.0% of the global HIV market was controlled by the leading ten players. However, GSK’s market leading position is under threat from increasing competition from Gilead and BMS.

The Global HIV/AIDS Market Outlook to 2012
Shifting epidemiological demographics within the HIV marketplace, increasing resistance to current therapies and unmet needs within the patient population... only an intrinsic understanding of these issues can secure the commercial success of new drug developments. The Global HIV/AIDS Market Outlook to 2012 is a new management report that provides comprehensive coverage of the global HIV/AIDS market, incorporating a detailed epidemiological analysis of the prevalence of HIV/AIDS and key factors impacting prevalence in both the seven major pharmaceutical markets as well as emerging markets. This report analyses current leading brands of treatment within the HIV market, provides invaluable insights into market dynamics, profiles the leading pharmaceutical companies and details the key market trends influencing product sales. This new report will enable you to plan more effectively, evaluate key changes in the competitive landscape and identify potential growth areas in the global HIV/AIDS market.

Top five reasons to order your copy today
• Identify treatment trends and quantify patient potential and sales patterns across the seven major and emerging markets and the 10 leading companies within the global HIV market.
• Benchmark the global HIV competitive landscape with this report’s strategic and growth analysis of market shares, sales focus by drug class, currently marketed products and R&D product
portfolios across leading players such as GSK, Gilead, BMS, Abbott, Roche, Boehringer Ingelheim, Pfizer, Merck, Barr and Kohl Medical.
• Discover which HIV drug classes have the greatest potential to provide franchise growth and understand key growth drivers for NRTIs, NNRTIs, protease inhibitors, and entry, integrase and maturation inhibitors.
• Understand the implications of key issues for major pharmaceutical marketers and new product development with this report’s assessment of the latest global HIV market intelligence.

Key issues examined in this report...
• FDA approval of the first once-daily triple-combination pill for the treatment of HIV. Atripla seem poised to redefine and expand the HIV market, surfacing as the new gold standard for first-line treatment with sales increasing by 101% from Q3 to Q4 in 2006.
• Entry of new drug classes redefining the HIV market. The forecast launch of integrase inhibitors, entry inhibitors and maturation inhibitors reflects the shifting demographics of HIV, the increasing resistance to current therapies and unmet patient needs.
• Potent new protease inhibitors offering additional treatment options in treatment-experienced patients. Approximately 42% of patients have demonstrated resistance to PIs, the availability of two new protease inhibitors offers additional treatment options.
• Trimeris/Roche's Fuzeon, the first-in-class fusion inhibitor entering the HIV market, offering an additional treatment option for patients requiring salvage therapy. Fuzeon has become the preferred agent for heavily treatment-experienced patients who require a therapy change.

Your questions answered...
• How much growth will be achieved by the global HIV market over the period 2006-2012?
• What will be the major growth drivers in the HIV market area over the period 2006-12?
• How have recent launches from companies such as Roche, Gilead and BMS performed?
• Which companies are best positioned to succeed in the global HIV market over the period 2006-12?
• What are the most exciting compounds currently in development for HIV, and what is the forecast market potential of these products?
• How significant is the threat of generics to the overall performance of the global HIV market?
• What will the competitive landscape within the global HIV market look like in 2012?